Who are lorlatinib plus chemotherapy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lorlatinib-plus-chemotherapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

lorlatinib plus chemotherapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

lorlatinib plus chemotherapy (lorlatinib plus chemotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ALK tyrosine kinase inhibitor (combination therapy). Area: Oncology.

marketed ALK tyrosine kinase inhibitor (combination therapy) ALK (anaplastic lymphoma kinase), ROS1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

lorlatinib plus chemotherapy (lorlatinib plus chemotherapy) — The First Affiliated Hospital of Guangzhou Medical University. Lorlatinib is an ALK tyrosine kinase inhibitor combined with chemotherapy to target ALK-positive cancers while enhancing cytotoxic effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
lorlatinib plus chemotherapy TARGET	lorlatinib plus chemotherapy	The First Affiliated Hospital of Guangzhou Medical University	marketed	ALK tyrosine kinase inhibitor (combination therapy)	ALK (anaplastic lymphoma kinase), ROS1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ALK tyrosine kinase inhibitor (combination therapy) class)

The First Affiliated Hospital of Guangzhou Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lorlatinib plus chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/lorlatinib-plus-chemotherapy. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab